Recursion Pharma director Blake Borgeson disposes of 30,000 shares valued at $100,200
Reuters2026/09/02 23:27- Recursion Pharmaceuticals director Blake Borgeson sold 30,000 Class A common shares on Sept. 1, 2026 at $3.34.
- Direct stake fell to 6,158,287 shares following the transaction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SK Hynix surges over 3% in pre-market trading
WashTec managing body member Michael Drolshagen buys shares for EUR 75,388
Gu Jingci: Bitcoin/Ethereum Trading Strategies and Market Analysis for September 5
The 550 billions USD investment agreement between Japan and the US sees new progress: the second batch of 73 billions USD projects launched, with AI and semiconductors as key areas of cooperation.
Japanese Minister of Economy, Trade and Industry Ryosei Akazawa stated that as part of a trade agreement reached with the United States last year, a 550 billions USD investment initiative is making progress.
